NYLIM
VIR icon

New York Life Investment Management’s Vir Biotechnology VIR Stock Holding History

New York Life Investment Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-35,766
Closed -$362K – 1312
2024
Q1 		$362K Buy
35,766
+20,867
+140% +$213K ﹤0.01% 1157
2023
Q4 		$150K Sell
14,899
-401
-3% -$3.66K ﹤0.01% 1304
2023
Q3 		$143K Sell
15,300
-2,411
-14% -$34.4K ﹤0.01% 1284
2023
Q2 		$434K Sell
17,711
-3,082
-15% -$77.4K ﹤0.01% 874
2023
Q1 		$484K Buy
+20,793
New +$532K 0.01% 827

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

New York Life Investment Management's VIR Position: Q2 2024 in Review

New York Life Investment Management sold out of Vir Biotechnology (VIR) in Q2 2024, closing a stake of 35,766 shares — an estimated $362K sold.

New York Life Investment Management first reported a position in VIR in Q1 2023 and held it in 5 quarters. The position peaked at $484K in Q1 2023. 215 funds tracked by Wall St. Rank hold VIR as of Q2 2024.

  • New York Life Investment Management reported no remaining Vir Biotechnology position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 35,766 Vir Biotechnology shares in Q2 2024, an estimated $362K.
  • New York Life Investment Management first reported a position in Vir Biotechnology in Q1 2023 and held it in 5 quarters.
  • New York Life Investment Management's Vir Biotechnology position peaked at $484K in Q1 2023.
  • 215 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.